title: Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women.
abstract: OBJECTIVE
  To determine whether percutaneous estradiol (pE2) (1.5 mg/day) is able to counteract the postmenopausal bone loss in postmenopausal hysterectomized women, in a double-blind study versus oral estriol (E3) (2 mg/day).
  
  
  METHODS
  The bone mineral density of the lumbar spine (LS) and of the proximal femur (PF) was measured every 3 months by dual energy X-ray absorptiometry for 2 years in 43 hysterectomized postmenopausal women (21 in the E2 group and 22 in the E3 control group), and in a subset of patients for a 3rd year. The statistical analyses were performed on Macintosh using Stat View II.
  
  
  RESULTS
  A significant bone loss of 1.2 (0.4%)% and of 1.3 (0.3)% per year was observed in the control group, respectively at LS and at PF, versus a significant gain of 1.2 (0.5)% per year in the treated group at the LS. No significant change at PF occurred in the treated group. In the 20 patients followed up for a 3rd year on pE2, an increase of 1.2 (0.9) and 2.5 (1.4)% at LS in the 12 former active group patients and the eight formerly control patients, respectively was seen. The same trend was observed at the proximal femur.
  
  
  CONCLUSIONS
  pE2 (1.5 mg E2) is able to counteract the postmenopausal bone loss in hysterectomized women, whereas E3 (2 mg/day administered orally) is unable to maintain bone mass.
authors.affiliation: Department of Rheumatology, St-Luc University Hospital, Brussels, Belgium. DEVOGELAER@RUMA.UCL.AC.BE
authors.forename: J P
authors.initials: JP
authors.lastname: Devogelaer
authors.forename: C
authors.initials: C
authors.lastname: Lecart
authors.forename: P
authors.initials: P
authors.lastname: Dupret
authors.forename: P
authors.initials: P
authors.lastname: De Nayer
authors.forename: C
authors.initials: C
authors.lastname: Nagant De Deuxchaisnes
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D004964:Estriol / Q000008:administration & dosage / Q000494:pharmacology; D015914:Estrogen Replacement Therapy / Q000379:methods* / Q000592:standards; D004970:Estrone / Q000097:blood; D005260:Female; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors
chemical_list: D004970:Estrone; D004958:Estradiol; D004964:Estriol